NCT04599881View on ClinicalTrials.gov

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

August 28, 2021

Study Completion Date

September 1, 2021

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
DRUG

PTR-01

IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses

Trial Locations (2)

80045

Children's Hospital Colorado, Aurora

94063

Stanford University, Redwood City

Sponsors
All Listed Sponsors
lead

Phoenix Tissue Repair, Inc.

INDUSTRY